Johnson & Johnson looks set to continue battling AbbVie over ad spend in the second half of 2026 as the U.S. Big Pharma’s immunology drug takes the top spot for a second quarter in a row, according to data from iSpot.tv.
J&J’s immunology med Tremfya saw spend for Q2 hit $115.3 million, beating out AbbVie’s rival Skyrizi at $108.7 million.
This kept Tremfya in its number one spot for the second quarter in a row. Skyrizi, however, moved up one spot quarter over quarter, displacing AbbVie’s sibling immunology therapy Rinvoq, which dropped down to third position.
The amount spent on Tremfya was nevertheless massively down from the $169.1 million J&J spent in Q1, while AbbVie coughed up $16.2 million less on Skyrizi ads over the same period.
That was something of a trend: Nine of the top 10 saw their spending on ads drop from the first to the second quarter.
The only pharma that charted a spending increase for the period was Teva with its Huntington’s disease chorea or tardive dyskinesia drug Austedo, though the boost was a scant $1 million quarter over quarter. This saw the medication reach the top 10 rankings, an achievement Teva could not claim back in Q1.
Check out the top 10 biggest pharma ad spenders for the second quarter below.
1. Tremfya
Movement: No movement vs. Q1 2026
What is it? Johnson & Johnson’s immunology drug
Est. national linear TV ad spend: $115.3 million (down from $169.1 million in Q1 2026)
- UC/Crohn’s disease: $64.1 million
- Psoriasis: $4.7 million
- Psoriatic Arthritis: $46.6 million
Top TV network by spend share of voice (SOV): ABC (20.93%)
Top TV program by spend SOV: Good Morning America (5.35%)
Number of spots: Nine (two psoriasis, four UC/Crohn’s disease, three psoriatic arthritis)
Biggest-ticket ad: “Relentless Weed” (est. $51 million)
2. Skyrizi
Movement: Up one spot
What is it? AbbVie’s immunology drug
Est. national linear TV ad spend: $108.7 million (down from $124.9 million in Q1 2026)
- UC/Crohn’s disease: $56 million
- Psoriasis: $46.1 million
- Psoriatic arthritis: $6.6 million
Top TV network by spend SOV: ABC (19.90%)
Top TV program by spend SOV: NBA (4.45%)
Number of spots: Six (two UC/Crohn’s disease, three psoriasis, one psoriatic arthritis)
Biggest-ticket ad: “I'm All In: Swimming Pool” (est. $36.4 million)
3. Rinvoq
Movement: Down one spot
What is it? AbbVie’s JAK immunology drug
Est. national linear TV ad spend: $91.2 million (down from $129.3 million in Q1 2026)
- UC/Crohn’s disease: $36.8 million
- Eczema: $26.2 million
- Arthritis: $28.2 million
Top TV network by spend SOV: ABC (23.17%)
Top TV program by spend SOV: Today (2.89%)
Number of spots: Six (two UC/Crohn’s disease, two arthritis, two eczema)
Biggest-ticket ad: “Classic Car, Tennis and Fire Station” (est. $36.7 million)
4. Zepbound
Movement: No change
What is it? Eli Lilly’s obesity drug
Est. national linear TV ad spend: $67.8 million (down from $74.9 million in Q1 2026)
Top TV network by spend SOV: CBS (21.36%)
Top TV program by spend SOV: NBA (14.07%)
Number of spots: 11
Biggest-ticket ad: “Watch This: Data” (est. $16.7 million)
5. Caplyta
Movement: No change
What is it? Johnson & Johnson’s atypical antipsychotic drug
Est. national linear TV ad spend: $55.6 million (down from $67.8 million in Q1 2026)
- MDD: $53.1 million
- Bipolar: $2.5 million
Top TV network by spend SOV: ABC (14.93%)
Top TV program by spend SOV: Good Morning America (4.57%)
Number of spots: Four (one bipolar, three MDD)
Biggest-ticket ad: “Let in the Lyte: More of the Lyte” (est. $19.3 million)
6. Rexulti (depression)
Movement: Up two spots
What is it? Lundbeck and Otsuka’s neurology drug
Est. national linear TV ad spend: $47.3 million (down from $52.3 million in Q1 2026)
Top TV network by spend SOV: CBS (14.49%)
Top TV program by spend SOV: NCIS (4.20%)
Number of spots: Two
Biggest-ticket ad: “Progress” (est. $47.3 million)
7. Dupixent
Movement: No change
What is it? Sanofi and Regeneron’s immunology drug
Est. national linear TV ad spend: $43.8 million (down from $52.6 million in Q1 2026)
- Eczema: $26.3 million
- Asthma: $17.4 million
- Gastrointestinal: $97K
Top TV network by spend SOV: ABC (30.37%)
Top TV program by spend SOV: NBA (9.45%)
Number of spots: Eight (three asthma, four eczema, one gastrointestinal)
Biggest-ticket ad: “Feel the Heal” (est. $15.5 million)
8. Jardiance
Movement: Up one spot
What is it? Eli Lilly and Boehringer Ingelheim’s diabetes and kidney disease drug
Est. national linear TV ad spend: $36.7 million (down from $51.9 million in Q1 2026)
- CKD: $9.5 million
- Diabetes: $27.2 million
Top TV network by spend SOV: ABC (18.16%)
Top TV program by spend SOV: NBA (5.96%)
Number of spots: Three (two CKD, one diabetes)
Biggest-ticket ad: “Behind the Scenes” (est. $27.2 million)
9. Vraylar
Movement: Up one spot
What is it? AbbVie’s atypical antipsychotic
Est. national linear TV ad spend: $32.8 million (down from $40.8 million in Q1 2026)
- Depression: $22.9 million
- Bipolar: $9.9 million
Top TV network by spend SOV: CBS (11.93%)
Top TV program by spend SOV: ABC World News Tonight With David Muir (4.11%)
Number of spots: Three (one bipolar, two depression)
Biggest-ticket ad: “Jane’s Head” (est. $22.7 million)
10. Austedo
Movement: Not listed in Q1 2026
What is it? Teva’s Huntington’s disease chorea or tardive dyskinesia drug
Est. national linear TV ad spend: $27.7 million (up from $26.7 million in Q1 2026)
Top TV network by spend SOV: CBS (29.51%)
Top TV program by spend SOV: Today With Jenna & Sheinelle (7.12%)
Number of spots: Two
Biggest-ticket ad: “Derek” (est. $14.6 million)